Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.
On September 25, 2025, NeuroSense Therapeutics Ltd. held its Annual General Meeting of Shareholders, where all proposed resolutions were approved. This event marks a significant step in the company’s governance and strategic planning, potentially impacting its future operations and stakeholder relations.
The most recent analyst rating on (NRSN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of treatments for neurodegenerative diseases. The company is based in Herzliya, Israel.
Average Trading Volume: 654,278
Technical Sentiment Signal: Sell
Current Market Cap: $30.51M
See more data about NRSN stock on TipRanks’ Stock Analysis page.